Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing

REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a ...